Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases

類似資料

• Efficacy and Safety Evaluation of Intrathecal Pemetrexed in EGFR-mutated NSCLC Patients 
with Leptomeningeal Metastases
  著者:: Tianli ZHANG, 等
  出版事項: (2025-08-01)
• Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR‐mutation non‐small cell lung cancer: A phase II single‐arm prospective clinical trial
  著者:: Lu, Zhi‐qin, 等
  出版事項: (2020)
• Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression
  著者:: White, Maya N, 等
  出版事項: (2021)
• Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series
  著者:: Li, Huiying, 等
  出版事項: (2019)
• Osimertinib administration via nasogastric tube in an EGFR‐T790M‐positive patient with leptomeningeal metastases
  著者:: Takeda, Takayuki, 等
  出版事項: (2017)